Biểu đồ giá cổ phiếu NTLA
NTLA Giá
Intellia Therapeutics Inc
$13.85
4.05%
$0.53
Khi đóng cửa: May 06, 16:00:00 GMT-4
$13.77
-0.57%
$-0.07
Phiên sau giờ: May 06, 20:00:00 GMT-4
Quay lại
Intellia Therapeutics Inc (NTLA) Giá
Thống kê chính
Giá đóng cửa trước
$13.31
Giá mở cửa
$13.25
Phạm vi ngày
$13.11 - $13.88
Phạm vi 52 tuần
$6.83 - $28.25
Khối lượng
3.8M
Khối lượng trung bình
5.1M
Tỷ suất cổ tức
--
EPS (TTM)
-3.83
Vốn hóa thị trường
$1.6B
NTLA là gì?
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 377 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The firm is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
